Trying to keep up with the rules for peptides feels a bit like trying to read a map while riding a roller coaster. Things are moving fast, and the FDA has recently put many popular substances into a category that makes them much harder to get from regular compounding pharmacies.
Why did my peptide just get labeled Category 2?
You might have noticed some of your favorites are now on a list called Category 2. In plain English, the FDA uses this list for substances that they believe have significant safety risks or lack enough data to prove they are safe for routine use.
Here is a quick look at who is on the list as of March 2026:
- BPC-157: Listed as Category 2 since September 2023 because of concerns about the immune system reacting poorly and a lack of safety data.
- TB-500: Also in Category 2. The FDA is worried about how it might trigger the immune system and notes there is no human exposure data available.
- CJC-1295 and Ipamorelin: Both were moved to Category 2. For CJC-1295, the FDA pointed to safety issues like an increased heart rate.
- GHK-Cu and GHRP-2: Both are listed in Category 2 due to concerns about how they might affect the immune system.
What about the peptides we see in the news?
If you are following the big names in weight loss, the data is much more detailed because they have gone through massive clinical trials. These trials are large-scale tests where scientists track exactly what happens to thousands of people over time.
Semaglutide showed a 14.9% weight loss in the STEP 1 trial and a 20% reduction in major heart-related events in the SELECT trial. However, more use means we see more safety signals.
Common issues reported include:
- Stomach trouble: Nausea and vomiting are very common.
- Digestion speed: It can cause delayed gastric emptying, which means food stays in your stomach longer.
- Emerging concerns: There are newer reports being watched for intestinal blockages and a rare eye condition called NAION, which is currently under review by European health officials.
Why are some peptides approved in other countries but not here?
It turns out the human body is complicated, and different countries have different rules for what they consider "proven." For example, Thymosin Alpha-1 is approved in over 35 countries as Zadaxin, but it is not FDA-approved in the U.S. In fact, a recent Phase III trial for its use in sepsis showed no reduction in deaths.
Similarly, Selank and Semax are approved in Russia, but the FDA still has them in Category 2, meaning they are considered substances of concern for now.
What should you do with this info?
Since these rules and safety reports change frequently, you should always check the latest status of anything you are considering. This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.